IMCR Q2 2025 Earnings — Immunocore Holdings plc Revenue & Financial Results | Market Cap Arena

IMCRImmunocore Holdings plc

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$98M+29.9% YoY

Gross Profit

$97M98.9% margin

Operating Income

-$15M-15.2% margin

Net Income

-$10M-10.5% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+4.3%

Cash Flow

Operating Cash Flow

$26M

Free Cash Flow

$26M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$694M

Stockholders' Equity

$388M

Cash & Equivalents

$488M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$98M	$75M	+29.9%
Gross Profit	$97M	$74M	+31.5%
Operating Income	-$15M	-$16M	+7.1%
Net Income	-$10M	-$12M	+11.3%

Revenue Segments

Sale of Therapies

$98M100%

Geographic Segments

UNITED STATES

$64M65%

Europe

$33M34%

Rest of World

$835,0001%